Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment

Inclusion Criteria: * Participant must be ≥ 18 to ≤ 85 years of age at the time of signing the Informed Consent Form (ICF). * Body mass index ≥ 18 kg/m2 to \< 40 kg/m2. * Female participants of childbearing potential must use at least one highly effective form of birth control. * Capable of giving signed informed consent. Participants with hepatic impairment only \- Diagnosis of chronic (≥ 6 months) and stable hepatic impairment (eg, no clinically significant change in signs, symptoms, or laboratory parameters of hepatic disease status within 30 days prior to study Screening). Exclusion Criteria: All participants * History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to cotadutide. * Any clinically important abnormalities in rhythm, conduction or morphology of the 12-lead resting electrocardiogram (ECG) and any clinically important abnormalities in the 12-lead ECG as considered by the Investigator that may interfere with the interpretation of QT interval corrected for heart rate using Fridericia's formula (QTcF), including abnormal ST-T-wave morphology, or left ventricular hypertrophy 1. Prolonged QTcF \> 470 ms or family history of long QT syndrome. 2. PR (PQ) interval shortening \< 120 ms. 3. PR (PQ) interval prolongation (\> 220 ms) intermittent or permanent second or third degree atrioventricular (AV) block, or AV dissociation. 4. Persistent or intermittent complete bundle branch block, or intraventricular conduction delay with QRS \> 119 ms. * Any evidence of additional severe or uncontrolled systemic disease or laboratory finding that makes it unsafe for the participant to participate in the study. * Impaired renal function, defined as estimated glomerular filtration rate (eGFR) \< 30 mL/minute/1.73 m2 at Screening. * Any positive result on Screening for serum hepatitis B surface antigen, anti-Core HBV antibody, hepatitis C antibody, or human immunodeficiency virus (HIV). * Any sign and confirmation of coronavirus disease 2019 (COVID19) infection: * Participants with concurrent or previous use of a glucagon-like peptide-1 (GLP1) receptor agonist. * Use of prohibited prescribed or nonprescribed medication during the 2 weeks prior to the first administration of Investigational Medicinal Product (IMP) or longer if the medication has a long half-life. * History of neoplastic disease within 5 years prior to Screening, except for adequately treated basal cell, squamous cell skin cancer, or in situ cervical cancer. * Presence of hepatocellular carcinoma or acute liver disease caused by an infection or drug toxicity. Participants with hepatic impairment only * Severe portal hypertension or surgical porto-systemic shunts. * Biliary obstruction or other causes of hepatic impairment not related to parenchymal disorder and/or disease of the liver. * Clinically relevant hepatic encephalopathy. * Severe ascites defined as ascites requiring paracentesis and albumin at 4-week intervals or less. * Fluctuating or rapidly deteriorating hepatic function, as indicated by strongly varying or worsening of clinical and/or laboratory signs of hepatic impairment within the 28-day Screening period. * Post liver transplantation. * Platelet count \< 50 × 109/L and/or neutrophil count \< 1.2 × 109/L and/or hemoglobin \< 8.5 g/dL or INR \>2.3. Participants with normal hepatic function only * History or presence of hepatic disease or evidence of other known forms of known chronic liver disease. * History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs. * Urinary albumin-to-creatinine ratio \> 3 mg/μmol.